PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma

Oncology Reports

Volumn 25, Issue 6, 2011, Pages 1621-1628

  Yang, Chuang ^a,b   Liu, Hai Zhong ^a   Lu, Wei Dong ^a   Fu, Zhong Xue ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b Third Hospital of Mianyang   (China)

Author keywords

Apoptosis; Colorectal carcinoma; Liposomes; Oxaliplatin

Indexed keywords

CASPASE 3; KI 67 ANTIGEN; LIPOSOME; MACROGOL; MESSENGER RNA; OXALIPLATIN; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; DRUG ACCUMULATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORECTAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LIPOSOMES; MICE; MICE, NUDE; ORGANOPLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79954511397     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1238     Document Type: Article

References (36)

1. Nobili S, Checcacci D, Filippelli F, et al: Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan-or oxaliplatin-based chemotherapy. J Chemother 20: 622-631, 2008.
2. Des GG, Lecaille C, Mariani P, et al: Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX. Anticancer Res 30: 4297-4301, 2010.
3. Tampellini M: Pharmacoeconomic aspects of FOLFIRI or FOLFOX regimens administered with a fully ambulatory pump compared to the day hospital setting. Tumori 96: 438-442, 2010.
4. Pasetto LM, D'Andrea MR, Rossi E, et al: Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol 59: 159-168, 2006.
5. Michor F, Iwasa Y, Lengauer C, et al: Dynamics of colorectal cancer. Semin Cancer Biol 15: 484-493, 2005.
6. Pietrangeli A, Leandri M, Terzoli E, et al: Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 56: 13-16, 2006. (Pubitemid 44359537)
7. Hussain S, Pluckthun A, Allen TM, et al: Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol Cancer Ther 6: 3019-3027, 2007. (Pubitemid 350206780)
8. Sun W, Zou W, Huang G, et al: Pharmacokinetics and targeting property of TFu-loaded liposomes with different sizes after intravenous and oral administration. J Drug Target 16: 357-365, 2008. (Pubitemid 351935733)
9. Allen TM, Hansen C, Martin F, et al: Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1066: 29-36, 1991.
10. Klibanov AL, Maruyama K, Beckerleg AM, et al: Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim Biophys Acta 1062: 142-148, 1991.
11. Allen C, Dos Santos N, Gallagher R, et al: Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep 22: 225-250, 2002. (Pubitemid 35222733)
12. Matsumura Y and Maeda H: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res 46: 6387-6392, 1986. (Pubitemid 17221789)
13. Yang C, Liu HZ and Fu ZX: Effect on apoptosis of human colorectal cancer SW480 cells induced by oxaliplatin long-circulating liposomes. J Third Mil Med Uni 33: 368-371, 2011.
14. Abu Lila AS, Kizuki S, Doi Y, et al: Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model. J Control Release 137: 8-14, 2009.
15. Thurston G, Mclean JW, Rizen M, et al: Cationic liposomes target angiogenic endothelial cells in tumours and chronic inflammation in mice. J Clin Invest 101: 1401-1413, 1998. (Pubitemid 28166838)
16. Bosman FT, Visser BC and van Oeveren J: Apoptosis: pathophysiology of programmed cell death. Pathol Res Pract 192: 676-683, 1996. (Pubitemid 26302242)
17. Cummings MC, Winterford CM and Walker NI: Apoptosis. Am J Surg Pathol 21: 88-101, 1997. (Pubitemid 127747155)
18. Staunton MJ and Gaffney EF: Apoptosis. Basic concepts and potential significance in human cancer. Arch Pathol Lab Med 122: 310-319, 1998.
19. Geske FJ and Gerschenson LE: The biology of apoptosis. Hum Pathol 32: 1029-1038, 2001. (Pubitemid 33015661)
20. Scott RJ, Hall PA, Haldane JS, et al: A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol 165: 173-178, 1991.
21. Kruger S and Muller H: Correlation of morphometry, nucleolar organizer regions, proliferating cell nuclear antigen and Ki-67 antigen expression with grading and staging in urinary bladder carcinomas. Br J Urol 75: 480-484, 1995.
22. Reed JC: Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 111: 3322-3330, 2008.
23. Tsamandas AC, Kardamakis D, Tsiamalos P, et al: The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome. Anticancer Res 29: 703-709, 2009.
24. Scopa CD, Tsamandas AC, Zolota V, et al: Potential role of bcl-2 and Ki-67 expression and apoptosis in colorectal carcinoma A clinicopathologic study. Dig Dis Sci 48: 1990-1997, 2003.
25. Soini Y, Paakko P and Letho V-P: Histopathological evaluation of apoptosis in cancer. Am J Pathol 153: 1041-1053, 1998.
26. Tabete S, Ishida M, Kasagi N, et al: Apoptosis occurs more frequent in metastatic foci than in primary lesions of human colorectal carcinomas: analysis by terminaldeoxynucleotidyl-transferase-mediated dUTP-biotin nick end labeling. Int J Cancer 65: 173-177, 1996.
27. Chipuk JE, Fisher JC, Dillon CP, et al: Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins. Proc Natl Acad Sci USA 105: 20327-20332, 2008.
28. Luo X, Budihardjo I, Zou H, et al: Bid, a Bcl-2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors Cell 94: 481-490, 1998.
29. Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326, 1998. (Pubitemid 28406819)
30. Jaattela M and Tschopp J: Caspase-independent cell death in T lymphocytes. Nat Immunol 4: 416-423, 2003.
31. Walters J, Pop C, Scott FL, et al: A constitutively active and uninhibitable caspase-3 zymogen efficiently induces apoptosis. Biochem J 424: 335-345, 2009.
32. Lee CM, Tanaka T, Murai T, et al: Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res 62: 4282-4288, 2002. (Pubitemid 34827283)
33. Jain A, Jain SK, Ganesh N, et al: Design and development of ligand-appended polysaccharide nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomedicine 6: 179-190, 2010.
34. Saito R, Bringas JR, McKnight TR, et al: Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res 64: 2572-2579, 2004. (Pubitemid 38523915)
35. Lappalainen K, Miettinen R, Kellokoski J, et al: Intracellular distribution of oligonucleotides delivered by cationic liposomes: light and electron microscopic study. J Histochem Cytochem 45: 265-274, 1997. (Pubitemid 27114496)
36. Atobe K, Ishida T, Ishida E, et al: In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP). Biol Pharm Bull 30: 972-978, 2007.